17 results about "Specific lysis" patented technology

The invention relates to the technical field of bacteriophages, and particularly discloses an acinetobacter baumannii bacteriophage, depolymerases and a preparation method and application of the acinetobacter baumannii bacteriophage. The acinetobacter baumannii bacteriophage P919 provided by the invention has very strong specific lysis capability on KL3 type acinetobacter baumannii, and the coded depolymerases of the acinetobacter baumannii bacteriophage P919 have excellent temperature stability at 70 DEG C or below, and can effectively degrade capsular polysaccharide of the KL3 type acinetobacter baumannii.

The invention belongs to the technical field of microorganisms, and discloses a phage capable of efficiently splitting escherichia coli and salmonella, a preparation and application of the phage, the name is SP1, the classification name is escherichia coli phage, the preservation number is CGMCC No.46440, the preservation date is China General Microbiological Culture Collection Center on May 30, 2025, and the preservation unit is China General Microbiological Culture Collection Center. The optimal infection complex number of the bacteriophage is 1, the bacteriophage has very strong acid resistance and thermal stability, and the bacteriophage can keep high titer under the conditions that the pH value is 4-11, the temperature is 10-70 DEG C and the ultraviolet irradiation is within 30 minutes. The incubation period of escherichia coli infected by the bacteriophage is about 30 min, the outbreak period is about 40 min after the incubation period, and the bacteriophage can specifically split escherichia coli and salmonella, does not contain virulence and drug-resistant genes and is high in biological safety.

The invention discloses an enterococcus faecalis bacteriophage vBEfaPFA2, a bacteriophage composition and application of the enterococcus faecalis bacteriophage vBEfaPFA2, the enterococcus faecalis bacteriophage vBEfaPFA2 has a specific lysis effect on enterococcus faecalis and also has a cross-species lysis effect on salmonella, the acid-base adaptability of the bacteriophage is high, and the bacteriophage vBEfaPFA2 and the bacteriophage composition can be used for preparing the enterococcus faecalis bacteriophage The enterococcus faecalis bacteriophage can be used as an active component to be prepared into the bacteriophage composition or the bacteriophage pharmaceutical preparation, the bacteriophage composition or the bacteriophage pharmaceutical preparation is applied to preparation of a medicine or a bacteriostatic agent for preventing and treating enterococcus faecalis and salmonella infection, the enterococcus faecalis bacteriophage and the bacteriophage composition are safe to use, high in yield and easy to industrially produce, and due to the cross-species lysis performance, the bacteriophage can be The method has the advantages of wide splitting spectrum, wide application range and good application prospect.

The invention provides an NPV linker sequence-based GD2 targeting antibody coupling drug, a preparation method and an application, and belongs to the technical field of biological medicines. According to the invention, an Asn-Pro-Val (NPV) sequence sensitive to neutrophil elastase is taken as a linker, and MMAE and Hu 3F8 are coupled by using a cysteine coupling technology, so that the antibody conjugate Hu 3F8-NPV-MMAE is obtained. The antibody conjugate shows good tumor cell killing ability, can significantly reduce the tumor volume, and is high in safety. And after passing through intercellular, the elastase of the antibody conjugate is split to release MMAE to play a role, so that the bystander effect can be enhanced, the curative effect of ADC can be improved, the drug-resistant mechanism related to ADC endocytosis and intracellular processing can be avoided, the enzyme specific splitting of Linker can be improved, and the toxic and side effects of ADC can be reduced.

The application discloses a method for eliminating passivation layer in bioleaching, a phage and application thereof, and belongs to the technical field of biohydrometallurgy. Mainly, the technical problem of passivation layer easily generated in the existing ore bioleaching process and low leaching efficiency is solved. The method utilizes the specific lysis of phage to the aging or overproliferation of bacteria adsorbed on the ore surface, destroys the passivation film structure composed of biofilm and sulfur-containing precipitate, exposes the fresh mineral surface, and thus significantly restores and improves the leaching efficiency of copper ions. The application has wide application prospect.

The invention relates to the technical field of molecular diagnosis technology, in particular to a method for detecting tigecycline resistance of klebsiella pneumoniae by mutation detection and application of the method. The method comprises the following steps: firstly, sampling a sample, adding a lysis solution containing a specific lysis enhancer, incubating at 37 DEG C, and then carrying out gradient centrifugation to take a supernatant; then extracting nucleic acid by using special bifunctional magnetic nanoparticles, washing and then eluting; preparing a PCR reaction system containing primers, enzyme and the like, and adding a novel auxiliary factor for amplification; then detecting mutation by using a compound nucleic acid dye through an HRM (High Resolution Melting) technology; and finally, comparing melting curves, and combining a machine learning algorithm to judge whether the sample is drug-resistant. The detection method has outstanding advantages; the innovative steps of sample treatment, nucleic acid extraction and detection improve the detection accuracy and efficiency, and can accurately identify low-level drug-resistant strains; meanwhile, the cost is greatly reduced, popularization in primary hospitals is facilitated, and great significance on prevention and control of drug-resistant bacteria is achieved.

Disclosed is a broad-spectrum phage for efficiently lysing Cronobacter, a bactericide, and use thereof. Also provided is a Cronobacter phage vB_CsaM_CBT2, where the phage has a deposit number of CCTCC NO: M 2023524. The phage only specifically lyses Cronobacter, has a broad lysis spectrum, and can cover four species of Cronobacter (including multi-drug-resistant bacteria). The phage shows a desirable stability at a pH value of 3 to 11 and 25° C. to 70° C., and has a bactericidal effect of 80.55% to 99.97% within 12 h in a milk powder sample. Moreover, the phage does not carry any virulence and antibiotic resistance genes, and meets the safety requirements in practical applications. Therefore, the phage provides a new strategy and resource guarantee for the control of Cronobacter contamination in powdered infant formula (PIF) and its industrial chain and environment, as well as the development of bactericides.

The invention relates to a lyase and a coding gene thereof, and application of the lyase in lysing bacteria. The bacteriophage capable of specifically splitting the vibrio parahaemolyticus is obtained through separation and purification, lyase is cloned from a genome of the bacteriophage, and after the lyase is subjected to prokaryotic expression and purification, the obtained protein shows the characteristics of the cleavable vibrio parahaemolyticus. The lyase disclosed by the invention has an obvious antibacterial effect on vibrio parahaemolyticus under the assistance of a permeable membrane agent, so that the lyase has a potential application value in the aspect of controlling pollution of the vibrio parahaemolyticus.

The invention discloses an enterococcus faecalis bacteriophage vBEfaPFA3, a bacteriophage composition and application of the enterococcus faecalis bacteriophage vBEfaPFA3, the enterococcus faecalis bacteriophage vBEfaPFA3 has a specific lysis effect on enterococcus faecalis and also has a cross-species lysis effect on salmonella, the acid-base adaptability of the bacteriophage is high, and the enterococcus faecalis bacteriophage vBEfaPFA3 can be used as an active component to be prepared into the bacteriophage composition or a bacteriophage pharmaceutical preparation. The enterococcus faecalis bacteriophage and the bacteriophage composition are applied to preparation of drugs or bacteriostatic agents for preventing and treating enterococcus faecalis and salmonella infection, are safe to use, have no side effects, are easy to industrially produce, and are wide in lysis spectrum and wide in application range based on the cross-species lysis performance of the enterococcus faecalis bacteriophage and the bacteriophage composition.

The application discloses a broad-spectrum bacteriophage targeting mucoid Escherichia coli, Cronobacter and Salmonella and application thereof Escherichia coli phage vB EcoP 3BB7B, the bacteriophage can specifically lyse colanic acid-producing mucoid Escherichia coli, and breaks through the technical bottleneck that a mucous layer limits adsorption of most bacteriophages; further has cross-species lysis capacity, not only has good lysis activity on mucoid Escherichia coli, but also can effectively lyse important foodborne pathogenic bacteria such as Salmonella of various serotypes and Cronobacter sakazakii, and significantly widens the host spectrum range. The bacteriophage can realize efficient amplification under the condition of a lower infection multiple, has good environmental stability, has strong lysis activity, does not carry drug resistance genes and virulence-related genes, has high safety, and has a good application prospect in clinical and food safety prevention and control.

The application discloses a tobacco Pseudomonas syringae bacteriophage YL1 and application thereof, and belongs to the technical field of biological control. The bacteriophage can specifically lyse the tobacco Pseudomonas syringae. The bacteriophage has the highest activity and the strongest lysis ability in the range of 30-60 DEG C and pH = 4-11, and has a wide lysis spectrum. Indoor test shows that the lysis rate of the bacteriophage to 23 strains of Pseudomonas syringae reaches 86.96%, and greenhouse potting test shows that the control effect of the bacteriophage reaches 90.82+ / -2.20%, so the bacteriophage has a good biocontrol effect on the tobacco Pseudomonas syringae.

The invention provides a GD2 targeting antibody coupling drug based on a BMOA linker sequence, and a preparation method and application thereof, and belongs to the technical field of biological medicines. The antibody conjugate Hu3F8-BMOA-MMAE is obtained by taking elastase sensitive BMOA as a novel connexon and coupling the novel connexon with a GD2 target antibody (Hu3F8) through a cysteine coupling technology. The antibody conjugate shows good tumor cell killing ability for tumor cells expressing GD2, and can target tumor cells, so that the antibody is directly released outside the cells after targeted binding, the tumor volume is remarkably reduced, and the safety is high. Moreover, MMAE is released through cracking of intercellular elastinase to play a role, so that the bystander effect can be enhanced, the curative effect of ADC can be improved, the drug resistance mechanism related to ADC endocytosis and intracellular processing can be avoided, the enzyme specific cracking of Linker can be improved, and the toxic and side effects of ADC can be reduced.

The present application relates to the technical field of bacteriophage, and discloses a bacteriophage of Pseudomonas syringae pv. actidii and application thereof, and the preservation number of the bacteriophage is CGMCC No. 45227. The bacteriophage provided by the present application can specifically lyse Pseudomonas syringae pv. actidii, and therefore, the bacteriophage can be used for preventing and treating bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial bacterial

This invention provides a method for isolating cell nuclei from *Pinus tabuliformis* tissue, relating to the field of plant molecular and cell biology. The method uses *Pinus tabuliformis* callus tissue as explants, releases protoplasts using a specific enzymatic hydrolysis solution, lyses them using a specific lysis buffer, and finally filters and centrifuges to obtain *Pinus tabuliformis* cell nuclei. Using this invention, cell nuclei suitable for single-cell and histone modification library construction and sequencing can be rapidly isolated, providing a foundation for research on single-cell nuclear genetic material transcription analysis, tissue-specific analysis, and cell fate determination in gymnosperms, and offering research ideas for the future use of cell nuclei in coniferous genetic engineering.

This invention relates to the field of phage technology, specifically disclosing an Acinetobacter baumannii phage, a depolymerase, its preparation method, and its applications. The Acinetobacter baumannii phage P919 provided by this invention exhibits strong specific lytic ability against Acinetobacter baumannii type KL3, and its encoded depolymerase possesses excellent temperature stability below 70°C, effectively degrading the capsular polysaccharide of Acinetobacter baumannii type KL3.

The invention discloses an enterococcus faecalis bacteriophage vBEfaPFA1, a bacteriophage composition and application of the enterococcus faecalis bacteriophage vBEfaPFA1, the enterococcus faecalis bacteriophage vBEfaPFA1 has a specific lysis effect on enterococcus faecalis and also has a cross-species lysis effect on salmonella, the acid-base adaptability of the bacteriophage is high, and the enterococcus faecalis bacteriophage vBEfaPFA1 can be used as an active component to be prepared into the bacteriophage composition or a bacteriophage pharmaceutical preparation. The enterococcus faecalis bacteriophage and the bacteriophage composition are applied to preparation of drugs or bacteriostatic agents for preventing and treating enterococcus faecalis and salmonella infection, are safe to use, have no side effects, are easy to industrially produce, and are wide in lysis spectrum and wide in application range based on the cross-species lysis performance of the enterococcus faecalis bacteriophage and the bacteriophage composition.

The invention relates to the technical field of microorganisms, and provides a bacteriophage perforin HolKpV318 with a broad-spectrum antibacterial effect and application of the bacteriophage perforin HolKpV318. The invention provides a potential novel antibacterial strategy aiming at the clinical problem of increasingly severe multi-drug-resistant klebsiella pneumoniae infection caused by antibiotic abuse at present, so as to overcome the defect that the traditional antibiotic treatment is invalid or poor in effect; the invention provides the perforin protein (HolKpV318) with efficient and specific klebsiella pneumoniae splitting capability, and the protein can form a pore channel on a klebsiella pneumoniae cell membrane to destroy the integrity of a bacterial structure so as to cause the death of target bacteria, so that a brand new biological preparation choice is provided for solving the problem of drug-resistant bacterium infection.